Cure8 research brief
Defining whether IBD therapies prevent long-term damage matters to patients and clinicians because it affects treatment goals and long-term care planning.
This review shows many real-world studies are not measuring the SPIRIT-recommended disease-modification outcomes, leaving uncertainty about long-term benefits of advanced treatments.
Clinicians, researchers, adult patients, and patients on biologics
This paper reviews real-world studies of ulcerative colitis and Crohn’s disease that purported to examine disease-modification with advanced treatments.
The authors compared study outcomes to SPIRIT-recommended disease-modification endpoints and found important gaps: key midterm outcomes (for example, fecal incontinence or bowel damage, proximal disease extension, permanent stoma, short-bowel symptoms) and long-term outcomes (cancer or mortality over recommended 5-year windows) were generally not assessed.
Many studies also did not use the recommended quality-of-life composites (IBDQ plus SF-36). The review concludes there is a need for prospective real-world studies that incorporate the SPIRIT-recommended endpoints so the field can better judge whether therapies truly change long-term IBD course.
whoShouldPayAttention: Clinicians and researchers designing IBD trials or observational studies, patients and advocates interested in long-term outcomes and disease-modification, and clinicians caring for patients on advanced therapies.
moreContext: Structured content depth is abstract: this brief is grounded in the article abstract and review text available from the journal. The article is a narrative review of existing real-world studies rather than a new interventional trial; it highlights gaps in outcome measurement rather than reporting new patient-level results.
summaryConfidence: high
The article is a narrative review (structured-content depth: abstract) summarizing gaps in outcome measurement across existing real-world studies; it does not present new trial data or patient-level outcomes.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Rising IBD prevalence across Asia means more people will need diagnosis, long-term care, and health-system resources; patterns differ by country and by Crohn's disease versus ulcerative colitis, which affects planning...
This registry study shows many people with IBD in Kazakhstan had clinically active disease at enrollment and identifies factors linked with active UC and CD. It highlights potential gaps in disease control and...
This roundup highlights new IBD research and real-world care issues that could influence future diagnosis, monitoring, and access to treatments. Findings on financial barriers and gaps in treat-to-target monitoring may...
